Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance

Sunwen Chou, Ronald J. Ercolani, E. Randall Lanier

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.

Original languageEnglish (US)
Pages (from-to)3845-3848
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

DNA-Directed DNA Polymerase
Cytomegalovirus
Mutation
Genes
Pressure
Exonucleases
Ganciclovir
Amino Acid Substitution
In Vitro Techniques
cidofovir hexadecyloxypropyl ester

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance. / Chou, Sunwen; Ercolani, Ronald J.; Lanier, E. Randall.

In: Antimicrobial Agents and Chemotherapy, Vol. 60, No. 6, 01.06.2016, p. 3845-3848.

Research output: Contribution to journalArticle

@article{3c04e614773349f7b4b62d20a925d19f,
title = "Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance",
abstract = "Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.",
author = "Sunwen Chou and Ercolani, {Ronald J.} and Lanier, {E. Randall}",
year = "2016",
month = "6",
day = "1",
doi = "10.1128/AAC.00214-16",
language = "English (US)",
volume = "60",
pages = "3845--3848",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Novel cytomegalovirus UL54 DNA Polymerase gene mutations selected in vitro that confer brincidofovir resistance

AU - Chou, Sunwen

AU - Ercolani, Ronald J.

AU - Lanier, E. Randall

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.

AB - Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L. The new exonuclease domain I resistance mutations selected under brincidofovir pressure add to the single instance previously reported and show the expected patterns of cross-resistance.

UR - http://www.scopus.com/inward/record.url?scp=84973655856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973655856&partnerID=8YFLogxK

U2 - 10.1128/AAC.00214-16

DO - 10.1128/AAC.00214-16

M3 - Article

C2 - 27044553

AN - SCOPUS:84973655856

VL - 60

SP - 3845

EP - 3848

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -